Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (708)	6/10/1999 2:15:00 PM
From: lrb	Read Replies (1) \| Respond to of 4974

"Cynthia Robbins-Roth, a.k.a. biogoddess, is ASAP's guest editor for this issue." forbes.com

To: scaram(o)uche who wrote (708)	6/10/1999 4:33:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 4974

I'm considering the wisdom of constructing a list of companies/products that encounter tox issues either after approval or in the latest stages of testing. Certainly, nobody would question that PFE might be listed rather frequently? In the latest case, Trovan, we are dealing with 14 confirmed cases of liver damage out of 2.5 million prescriptions. It apparently didn't show up in their 7,000 person trials. I really don't think this is something we can blame the company for - it just seems to be bad luck that an idiosyncratic reaction is unusually severe. Peter